PD-L1 expression and PD-1 checkpoint pathway in cancer was enriched across all three treatments, while the T cell receptor signaling pathway was enriched in ICIs monotherapy and ICIs combined with angiogenesis inhibitor therapy, and the vascular endothelial growth factor signaling pathway was observed in ICIs combined with angiogenesis inhibitor therapy (Supplemental Fig. S8B). This evidence concerns the gene VEGFA and cancer.